Tests GI-102 alone and with other drugs in advanced solid tumors
Tests GI-102, alone or with other cancer drugs, in adults with advanced solid tumors.
Key facts
- Who runs it
- GI Innovation, Inc.
- Where
- Cleveland, Jacksonville, New York, Rochester, and Scottsdale, United StatesSee the 5 sitesAlso in 1 other country, 5 sites
- Trial code
- Registry title
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 358 people, planned
- Started
- 30 May 2023
- Expected to end
- 24 Apr 2027
- Type of study
- Interventional, 7 groups
- Treatments tested
- GI-102 subcutaneous (SC)
- GI-102
- doxorubicin
- paclitaxel
- bevacizumab
- eribulin
- trastuzumab deruxtecan (T-DXd)
- pembrolizumab
- Record updated
- 25 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic solid tumors that can be measured, who are fairly active in daily life.
- Age
- 18 years or older (19 or older where local rules say so)
- Sex
- Men and women
- Disease stage
- Advanced or metastatic solid tumor with measurable disease (RECIST v1.1); daily-life activity score ECOG 0-1
- Earlier treatment
- Side effects from earlier cancer treatment or surgery must have settled to Grade 1 or lower, except hair loss and Grade 2 nerve damage in hands or feet. People living with HIV can join if on anti-retroviral therapy with well-controlled HIV.
Main reasons for not taking part
- Active brain metastases or cancer in the membranes around the brain
- Another active cancer
- Active or past Hepatitis B, or active Hepatitis C
- Active autoimmune disease needing systemic treatment in the past 2 years
- Cancer treatment within 4 weeks before the study, or radiotherapy within 2 weeks
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening
- Has adequate organ and marrow function as defined in protocol
- Measurable disease as per RECIST v1.1
- ECOG performance status 0-1
- Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy, other prior systemic anti-cancer therapy, or surgery must have resolved to Grade ≤1, except alopecia and Grade 2 peripheral neuropathy
- HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease as defined in protocol
Who cannot take part
- Active or uncontrolled infections, or severe infection within 4 weeks before study treatment administration
- Previous immunotherapies related to mode of action of GI-102
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive medications within 2 weeks prior to Cycle 1 Day 1
- Administration of prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment
- Radiotherapy within the last 2 weeks before start of study treatment administration, with exception of limited field palliative radiotherapy
- Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1
- An active second malignancy
- Has active or a known history of Hepatitis B or known active Hepatitis C virus infection
- Has active tuberculosis or has a known history of active tuberculosis
- History of chronic liver disease or evidence of hepatic cirrhosis, except patients with liver metastasis
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Known hypersensitivity to any of the components of the drug products and/or excipients of GI-102; Other protocol defined inclusion exclusion criteria may apply
- Has known active CNS metastases and/or carcinomatous meningitis
Where in United States
Also in 1 other country, 5 sites
- Cleveland ClinicCleveland, United StatesContact: Wen Wee Ma, MBBSTaking people
- Mayo Clinic in FloridaJacksonville, United StatesContact: Yujie Zhao, MD, PhDTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Viswatej Avutu, MDTaking people
- Mayo Clinic in MinnesotaRochester, United StatesContact: Jian Li Campian, MD, PhDTaking people
- Mayo Clinic in ArizonaScottsdale, United StatesContact: Mahesh Seetharam, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.
The 7 groups in the trial
- GI-102Treatment being tested
Dose escalation: GI-102 intravenous (IV), multiple ascending doses Dose optimization: GI-102 intravenous (IV), sRP2D Dose optimization: GI-102 intravenous (IV), sRP2D-1 (or sRP2D+1)
- GI-102 subcutaneous (SC)Treatment being tested
Dose escalation: GI-102 subcutaneous (SC), multiple ascending doses Dose expansion: GI-102 subcutaneous (SC), sRP2D
- GI-102 + doxorubicinTreatment being tested
Treatment: doxorubicin and GI-102
- GI-102 + paclitaxel + bevacizumabTreatment being tested
Treatment: paclitaxel, bevacizumab, and GI-102
- GI-102 + eribulinTreatment being tested
Treatment: eribulin and GI-102
- GI-102 + trastuzumab deruxtecan (T-DXd)Treatment being tested
Treatment: trastuzumab deruxtecan (T-DXd) and GI-102
- GI-102 + pembrolizumabTreatment being tested
Treatment: pembrolizumab and GI-102
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)
- Plain-language title
- Tests GI-102 alone and with other drugs in advanced solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 November 2024